# Moderna Moat

Status: published. Policy: company-analysis-1.

Moderna has valuable vaccine approvals, monetized intellectual property and government manufacturing relationships, but demonstrated commercial weakness outweighs evidence of a durable economic moat. New product adoption and government-linked growth are meaningful positives; multiyear demand declines, minimal RSV sales, more attractive competitor terms and costly manufacturing and patent obligations show fragility. Higher average selling prices in 2023 demonstrate some realized pricing ability, but sustained pricing power is unproven.

## intangible_assets

Approved vaccines and income-producing intellectual property provide current commercial value, but do not establish durable competitive protection. Government manufacturing agreements support demand visibility without demonstrating customer lock-in or superior production economics.

Durability: Four approved products by June 2026 and realized licensing receipts demonstrate capabilities. Patent exclusivity duration, durable product differentiation and sustained customer preference are not established. Shared manufacturing efficiencies and pipeline expansion remain potential advantages.

Risks: Established vaccine competitors, weak RSV adoption, declining underlying demand, third-party patent dependencies and settlement expenses constrain value capture. Government-linked deliveries may support revenue without proving broader competitive strength.

Invalidation: The limited intangible-asset advantage would weaken further if approvals fail to generate recurring demand, licensing receipts cease, or patent obligations materially restrict commercialization. The no-moat conclusion would warrant reassessment if multiple products sustain adoption and favorable realized prices across successive seasons while manufacturing utilization improves and patent costs stabilize.

Competitors: Pfizer, BioNTech, Sanofi, Novavax, GlaxoSmithKline
- [https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm) · 2026-02-20
- [https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm) · 2026-07-31
- [https://www.sec.gov/Archives/edgar/data/1682852/000130817926000081/mrna-20260316.htm](https://www.sec.gov/Archives/edgar/data/1682852/000130817926000081/mrna-20260316.htm) · 2026-03-16
- [https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm) · 2025-02-21
- [https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm](https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm) · 2024-02-23
- [https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm) · 2026-05-01

[JSON](https://beanvest.com/stock/mrna/moat.json)